Geode Capital Management LLC Boosts Stock Position in Codexis, Inc. (NASDAQ:CDXS)

Geode Capital Management LLC raised its holdings in Codexis, Inc. (NASDAQ:CDXS) by 12.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,855,514 shares of the biotechnology company’s stock after buying an additional 211,475 shares during the period. Geode Capital Management LLC owned about 2.28% of Codexis worth $8,853,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Kingswood Wealth Advisors LLC acquired a new stake in shares of Codexis during the 4th quarter worth about $79,000. China Universal Asset Management Co. Ltd. purchased a new position in Codexis in the fourth quarter valued at approximately $82,000. Intech Investment Management LLC raised its holdings in Codexis by 55.1% during the fourth quarter. Intech Investment Management LLC now owns 33,111 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 11,757 shares in the last quarter. Corebridge Financial Inc. lifted its position in shares of Codexis by 7.2% during the 4th quarter. Corebridge Financial Inc. now owns 40,052 shares of the biotechnology company’s stock worth $191,000 after buying an additional 2,703 shares during the last quarter. Finally, Jackson Square Capital LLC purchased a new stake in shares of Codexis during the 4th quarter worth approximately $210,000. 78.54% of the stock is owned by hedge funds and other institutional investors.

Codexis Trading Up 2.2 %

NASDAQ CDXS opened at $2.28 on Thursday. The firm’s fifty day moving average price is $2.81 and its 200 day moving average price is $3.82. Codexis, Inc. has a 12 month low of $1.90 and a 12 month high of $6.08. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15. The company has a market capitalization of $188.87 million, a price-to-earnings ratio of -2.62 and a beta of 2.35.

Codexis (NASDAQ:CDXS) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.09). Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. The firm had revenue of $21.46 million for the quarter, compared to analysts’ expectations of $27.41 million. On average, sell-side analysts expect that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.